Clinical Trials Browser

Phase 1/2 × Pancreatic Neoplasms × camrelizumab × Clear all

NCT05218889 2024-12-31

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms